Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
Status:
Completed
Trial end date:
2019-11-27
Target enrollment:
Participant gender:
Summary
Phase I study. To determine the MTD (Maximum Tolerated Dose) of nintedanib + weekly Docetaxel
in patients with locally advanced or metastatic lung adenocarcinoma after failure of
platinum-based first line chemotherapy.